A detailed history of Pro Share Advisors LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 11,142 shares of RARE stock, worth $618,938. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,142
Previous 6,074 83.44%
Holding current value
$618,938
Previous $283,000 61.48%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$37.42 - $51.61 $189,644 - $261,559
5,068 Added 83.44%
11,142 $457,000
Q1 2024

May 08, 2024

BUY
$43.02 - $53.69 $20,907 - $26,093
486 Added 8.7%
6,074 $283,000
Q4 2023

Feb 14, 2024

BUY
$31.73 - $49.19 $177,307 - $274,873
5,588 New
5,588 $267,000
Q2 2023

Aug 10, 2023

SELL
$37.35 - $52.15 $25,285 - $35,305
-677 Reduced 12.45%
4,762 $219,000
Q1 2023

May 11, 2023

SELL
$36.99 - $48.71 $52,636 - $69,314
-1,423 Reduced 20.74%
5,439 $218,000
Q4 2022

Feb 02, 2023

SELL
$33.72 - $46.33 $4,889 - $6,717
-145 Reduced 2.07%
6,862 $317,000
Q3 2022

Nov 04, 2022

BUY
$39.96 - $66.14 $16,543 - $27,381
414 Added 6.28%
7,007 $290,000
Q2 2022

Aug 01, 2022

SELL
$45.8 - $85.4 $98,286 - $183,268
-2,146 Reduced 24.56%
6,593 $393,000
Q1 2022

May 10, 2022

SELL
$62.2 - $84.4 $159,978 - $217,076
-2,572 Reduced 22.74%
8,739 $634,000
Q4 2021

Feb 08, 2022

SELL
$73.71 - $87.86 $352,849 - $420,585
-4,787 Reduced 29.74%
11,311 $951,000
Q3 2021

Nov 12, 2021

BUY
$77.92 - $102.4 $130,905 - $172,032
1,680 Added 11.65%
16,098 $1.45 Million
Q2 2021

Aug 13, 2021

SELL
$92.19 - $115.71 $1.2 Million - $1.51 Million
-13,010 Reduced 47.43%
14,418 $1.38 Million
Q1 2021

May 14, 2021

BUY
$106.9 - $167.73 $243,197 - $381,585
2,275 Added 9.04%
27,428 $3.12 Million
Q4 2020

Feb 09, 2021

BUY
$84.4 - $177.39 $620,593 - $1.3 Million
7,353 Added 41.31%
25,153 $3.48 Million
Q3 2020

Nov 13, 2020

SELL
$72.98 - $90.0 $26,564 - $32,760
-364 Reduced 2.0%
17,800 $1.46 Million
Q2 2020

Aug 03, 2020

BUY
$46.91 - $78.22 $282,773 - $471,510
6,028 Added 49.67%
18,164 $1.42 Million
Q1 2020

May 15, 2020

SELL
$33.8 - $62.9 $306,329 - $570,062
-9,063 Reduced 42.75%
12,136 $539,000
Q4 2019

Feb 12, 2020

SELL
$36.08 - $45.83 $69,201 - $87,901
-1,918 Reduced 8.3%
21,199 $905,000
Q3 2019

Nov 12, 2019

SELL
$42.5 - $63.11 $23,290 - $34,584
-548 Reduced 2.32%
23,117 $989,000
Q2 2019

Aug 13, 2019

SELL
$54.93 - $74.36 $182,697 - $247,321
-3,326 Reduced 12.32%
23,665 $1.5 Million
Q1 2019

May 15, 2019

BUY
$39.87 - $69.36 $136,634 - $237,696
3,427 Added 14.54%
26,991 $1.87 Million
Q4 2018

Feb 14, 2019

SELL
$38.89 - $77.3 $167,927 - $333,781
-4,318 Reduced 15.49%
23,564 $1.03 Million
Q3 2018

Nov 14, 2018

SELL
$71.81 - $90.15 $23,481 - $29,479
-327 Reduced 1.16%
27,882 $2.13 Million
Q2 2018

Aug 13, 2018

SELL
$48.54 - $85.31 $77,858 - $136,837
-1,604 Reduced 5.38%
28,209 $2.17 Million
Q1 2018

May 14, 2018

SELL
$44.33 - $58.52 $3,280 - $4,330
-74 Reduced 0.25%
29,813 $1.52 Million
Q4 2017

Feb 14, 2018

BUY
$43.54 - $57.32 $100,664 - $132,523
2,312 Added 8.38%
29,887 $1.39 Million
Q3 2017

Nov 13, 2017

BUY
$49.79 - $66.32 $76,676 - $102,132
1,540 Added 5.92%
27,575 $1.47 Million
Q2 2017

Aug 11, 2017

BUY
N/A
26,035
26,035 $1.62 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.89B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.